Signant Health

Hospital readmissions after heart failure are a major clinical and public health concern. These high rates of readmission contribute to increased patient morbidity and healthcare cost. At ESC Congress this week, we’ll co-present findings from our research collaboration with University of Leeds which indicates how a quality-of-life measure can identify heart failure patients at high risk of rehospitalization or death. Connect with Maria Visser and Elias Ketiar MD MD(Res) MRCP on site in Madrid to get the details and explore how patient-reported outcomes may enhance trial design and patient care. #ESCCongress2025 #WCCardio #cardiology #clinicaltrials #eCOA #ePRO

Still operating with supply chain blind spots? Most clinical trial sponsors rely on disconnected systems that turn manageable supply issues into costly and time-consuming crises. When quality events or manufacturing delays hit, fragmented visibility can impact timelines and patient safety. Our new white paper reveals how integrated RTSM and supply management software creates end-to-end visibility and control – from API production to patient dosing. Learn how to transform reactive firefighting into proactive supply optimization. Get it here → https://lnkd.in/dNTGQE2i #clinicalsupplies #supplychain #IRT

What can we learn from schizophrenia programs that successfully advance to Phase III? On September 24, join world-renowned expert Professor Jeffrey Lieberman and our panel of CNS specialists as we examine evidence-based de-risking strategies for optimizing trial outcomes and enhancing the probability of success. Not just theoretical, we'll dive into real lessons learned from recent trials, plus explore how AI technology and methodological innovations are transforming patient selection, endpoint measurement, and signal detection in schizophrenia clinical development. Reserve your seat: https://hubs.li/Q03Dx-KS0   David Daniel Alan Kott Christopher Murphy #ClinicalTrials #CNS #SchizophreniaResearch

Managing clinical trials with a lean team? You know the struggle: tight budgets, protocol changes mid-study, and needing system updates yesterday. After 20+ years with biotech teams, we've compiled 10 strategies that help small teams make smart EDC decisions and avoid costly rework. Get the strategies → https://hubs.li/Q03Dr4LL0 #Biotech #EDC #ClinicalTrials

Remember when COA data meant boxes of paper questionnaires and patient diaries? We started digitalizing clinical trials when smartphones were science fiction. 25 years later, we're still solving tomorrow's problems today. #25YearsofSignant #eClinicalInnovation

Regulatory approval for weight management therapies requires more than weight scale readings; HTA bodies are looking for robust patient-reported outcomes demonstrating meaningful treatment impact beyond the scale. Successful sponsors build complete evidence cases that track mood, appetite, quality of life, and body image. Our eCOA platform has supported 40+ obesity trials and 3 successful regulatory approvals of major weight management therapies. Capture clean, complete data from early phase to Phase III: https://lnkd.in/grqhXrj7

For 25 years, we've been turning clinical data into life-changing evidence. From Palm Pilots to AI-powered analytics, we've evolved with every breakthrough. Here's to 25 years of evidence generation – and the next 25 years of innovation ahead. #25YearsOfSignant #eClinicalInnovation

Signal detection in movement disorder trials can be challenging due to unwanted endpoint data variability, usually a result of complex, subjective clinician rating scales such as UPDRS, AIMS, or YGTSS. Our eCOA and enhanced clinician rating solutions have delivered reliable, regulatory-ready data for 250+ movement disorder studies in 44 countries. Learn how we facilitate accurate movement disorder measurement → https://hubs.li/Q03yK_0f0 #clinicaltrials #Parkinsons #eCOA #eClinRO #tardivedyskinesia

When rating variability masks treatment signals, even promising CNS therapies can fail to show efficacy. Rater Station® addresses this with detailed, scale-specific guidance, automated scoring validation, and workflows that support clinical expertise. Learn how electronic clinician ratings ensure endpoint reliability → https://hubs.li/Q03yttLv0 #CNS #clinicaltrials #dataquality

Immunology trials face a common challenge: complex, subjective rating scales that can make or break your study outcomes. Indications such as lupus and psoriatic arthritis (PsA) rely heavily on ClinRO measures that can be vulnerable to variability, scoring errors, and placebo response—all of which can obscure true treatment effects. The solution?   What makes a difference:   1. Electronic rating scales with built-in guidance  2. Rater training to standardize assessment technique  3. Analytics to catch quality issues before impact  4. Central review by expert raters to capture ratings drift   De-risk your immunology program. Take a look at how we've implemented some of these strategies in a recent PsA trial: https://hubs.li/Q03xFGj20